Drug Detail

Information about Ziftomeinib + Imatinib

Generic Name	Ziftomeinib + Imatinib
IND
Brand Name (US)
Manufacturer
Drug Type
Delivery	Oral
Approval Status	Phase 1/2
Indications	GIST
Overall Strategy	Synthetic lethality via KIT
Strategy	Degrade KIT and stop KIT epigenetic transcription
Drug Category	Menin + KIT/PDGFRA inhibitor

Possible mechanism of action. Imatinib causes vulnerability that can be targeted by ziftomenib at the transcriptional and/or protein stability levels, creating synthetic lethality.